Jonathan James Butcher

Jonathan joined BioVersys in May 2018 and leads the business development activities with passion and dedication. Within a short time, Jonathan impacted the business of BioVersys with in-licensing and acquisition deals, while leading the non-dilutive fund-raising activities that resulted in European Union IMI and CARB-X awards. Jonathan also supports the company’s capital fund-raising activities. Prior to BioVersys, he was Head of Business Development for Polyphor’s Drug Discovery Unit, where he secured drug discovery collaboration & licensing deals with leading global pharmaceutical and biotech companies. At Polyphor he also led the valuation of Polyphor’s pipeline assets, Murepavidin (POL7080) - Phase III Pseudomonas aeruginosa selective antibiotic, licensed to Roche in 2013, US$547 million, and POL6014 - Phase Ib selective elastase inhibitor for respiratory diseases, licensed to Santhera in 2018, US$130 million. Prior to Polyphor, Jonathan led Hit-2-Lead and medicinal chemistry projects at Evotec, UK. Jonathan obtained his Ph.D. in organic chemistry from the University of Reading, England, and is the co-author of a number of scientific publications and patents.